Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan
2017年6月8日 - 11:07AM
JCN Newswire (英)
Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica
OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating
tablet), a new formulation following pain treatment Lyrica Capsules
(pregabalin), will be launched on June 8.
Lyrica Capsules are co-promoted in Japan by Pfizer and Eisai, with
both companies working to provide information on its proper use.
Likewise, Lyrica OD Tablets will also be co-promoted by both
companies in Japan.
Lyrica is indicated for use in patients with neuropathic pain and
pain associated with fibromyalgia. Many of these patients are
elderly, and there are cases of patients having difficulty
swallowing. Lyrica OD Tablets dissolve swiftly inside the mouth,
making it an easy form for these patients to take, and are expected
to lead to increased convenience when taking medicine.
Through Lyrica, Pfizer and Eisai will continue to contribute to
improvement of quality of life in patients suffering from
neuropathic pain and pain associated with fibromyalgia.
http://www.acnnewswire.com/topimg/Low_EisaiLyrica.jpg
About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human
health care (hhc) company that discovers, develops and markets
products throughout the world. Eisai focuses its efforts in three
therapeutic areas: integrative neuroscience, including neurology
and psychiatric medicines; integrative oncology, which encompasses
oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of
research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the
worldwide healthcare system. For more information about Eisai Co.,
Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Corporate Communications
Pfizer Japan Inc.
Telephone: +81-3-5309-6644
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Copyright 2017 JCN Newswire . All rights reserved.